References
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Annex 10, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, WHO Technical Report Series, No. 1010, 2018. [cited 2021 April 23]. https://apps.who.int/iris/bitstream/handle/10665/272452/9789241210195-eng.pdf.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Stability testing of new drug substances and products, Q1A(R2), 2003. [cited 2021 April 23]. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Pharmaceutical Development, Q8(R2), 2009. [cited 2021 April 23]. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf.
- The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), Note for guidance on in-use stability testing of human medicinal products, CPMP/QWP/2934/99, 2001. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products_en.pdf.
- The European Agency for the Evaluation of Medicinal Products, Committee for Veterinary Medicinal Products, Note for guidance on in-use stability testing of veterinary medicinal products (excluding immunological veterinary medicinal products), EMEA/CVMP/424/01-Final, 2002. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-veterinary-medicinal-products-excluding-immunological-veterinary_en.pdf.
- The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution, CPMP/QWP/159/96 corr., 1998. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-maximum-shelf-life-sterile-products-human-use-after-first-opening-following_en.pdf.
- The European Agency for the Evaluation of Medicinal Products, Committee for Veterinary Medicinal Products, Note for guidance on maximum shelf-life for sterile medicinal products after first opening or following reconstitution, EMEA/CVMP/198/99-FINAL, 2000. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-maximum-shelf-life-sterile-medicinal-products-after-first-opening-following_en.pdf.
- European Medicines Agency, Committee for medicinal products for veterinary, Guideline on data requirements to support in-use stability claims for veterinary vaccines, EMA/CVMP/IWP/250147/2008, 2010. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-support-use-stability-claims-veterinary-vaccines_en.pdf.
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, #242, Guidance for industry, In-use stability studies and associated labeling statements for multiple-dose injectable animal drug products, 2020. [cited 2021 April 23]. https://www.fda.gov/media/102469/download.
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for industry, Current good manufacturing practice - Guidance for human drug compounding outsourcing facilities under section 503B of the FD&C Act, 2020. [cited 2021 April 23]. https://www.fda.gov/media/88905/download.
- USP Compounding Standards and Beyond-Use Dates (BUDs), 2019. [cited 2021 April 23]. https://www.usp.org/sites/default/files/usp/document/our-work/compounding/usp-bud-factsheet.pdf.
- ASEAN guideline on stability study of drug product, 20th ASEAN Consultative Committee for Standards and Quality - Pharmaceutical Product Working Group Meeting, Bali, Indonesia, 2013. [cited 2021 April 23]. https://asean.org/wp-content/uploads/2012/10/ASEAN-Guideline-on-Stability-Study-of-Drug-Product-R1-2013.pdf.
- Executive Board of the Health Ministers’ Council for GCC States, The GCC Guidelines for Stability Testing of Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs), Version 3.1, 2011. [cited 2021 April 23]. https://old.sfda.gov.sa/en/drug/resources/Guides/The%20GCC%20Guidelines%20for%20Stability%20Testing%20%20version%203.1%2024-2-2013.pdf.
- Ricci MS, Frazier M, Moore J, et al. In-use physicochemical and microbiological stability of biological parenteral products. Am J Health Syst Pharm. 2015;72(5):396–407.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Stability testing: Photostability testing of new drug substances and products, Q1B, 1996. [cited 2021 April 23]. https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf.
- Matthews BR. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm. 1999;25(7):831–856.
- Bowen L, Mangan M, Haywood A, et al. Stability of frusemide tablets repackaged in dose administration aids. J Pharm Pract Res. 2007;37(3):178–181.
- Australian product information, Uremide, Furosemide (frusemide) tablet, Mylan. [cited 2021 April 23]. https://apps.medicines.org.au/files/afpuremi.pdf.
- Mukharya A, Patel PU, Chaudhary S. Evaluation of “in-Use” stability period of lacidipine tablets in multi-dose plastic container-closure. PCI- Approved-Ijpsn. 2013;6(2):2022–2032.
- Woo N, Lee N, Lee S, et al. In-use stability study of phloroglucinol and nitroglycerin sublingual tablets using simulation design after opening of their containers. Yakhak Hoeji. 2017;61(6):281–285.
- Nguyenpho A, Ciavarella AB, Siddiqui A, et al. Evaluation of in-use stability of anticoagulant drug products: Warfarin sodium. J Pharm Sci. 2015;104(12):4232–4240.
- Public Assessment Report of the Medicines Evaluation Board in the Netherlands, Galantagen Retard 8 mg, 16 mg and 24 mg, prolonged-release capsules, hard, Mylan B.V., The Netherlands, Galantamine (as hydrobromide), 2012. [cited 2021 April 23]. https://mri.cts-mrp.eu/Human/Downloads/NL_H_2053_002_PAR.pdf.
- Summary of Product Characteristics, Galantamine Retard Mylan 8 mg, 16 mg and 24 mg, hard prolonged release capsules. [cited 2021 April 23]. https://mri.cts-mrp.eu/human/downloads/NL_H_2030_003_FinalPI.pdf.
- Dharani S, Barakh Ali SF, Afrooz H, et al. Quality and in-use stability comparison of Brand and generics of extended-release phenytoin sodium capsules. J Pharm Sci. 2019;108(5):1808–1817.
- DailyMed, Dilantin - extended phenytoin sodium capsule, Parke-Davis, Division of Pfizer Inc. [cited 2021 April 23]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8848de76-8d74-4620-bcc7-a86a596e5dd9.
- Yagoub YMM, Abdoun S, Seri HI. In-use stability studies of two veterinary medicinal products: Albendazole and oxytetracycline. Assiut Vet. Med. J. 2013;59:11–15. [cited 2021 April 23]. http://www.aun.edu.eg/journal_files/92_J_4147.pdf.
- Agrar Holland BV. Albendazole 2.5% – Broad spectrum anthelmintic oral suspension. [cited 2021 April 23]. https://www.agrar.nl/gb/wp-content/uploads/2019/03/ALBENDAZOLE25_oral_solution.pdf.
- Vega-Zambrano CDP, Villegas Vílchez LF. Evidencing the impact of drug store storage conditions on the quality and stability of amoxicillin powders for oral suspension marketed in Peru. J. Appl. Pharm. Sci. 2019;9:88–93. [cited 2021 April 23].
- Amoxil (Amoxicillin) capsules, tablets, or powder for oral suspension. [cited 2021 April 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/50542s02950754s01950760s01950761s016lbl.pdf.
- Potier A, Voyat J, Nicolas A. Stability study of a clonidine oral solution in a novel vehicle designed for pediatric patients. Pharm Dev Technol. 2018;23(10):1067–1076.
- Electronic Medicines Compendium, Clonidine Hydrochloride 50mcg/5ml Oral Solution, SmPC, Thame Laboratories, 2020. [cited 2021 April 23]. https://www.medicines.org.uk/emc/product/9616/smpc#gref.
- Abdelazim OA, Ali RS, Eissa RA. In-use stability study of paracetamol syrup, College of Science, Sudan University for Science and Technology, 2016. [cited 2021 April 23]. http://repository.sustech.edu/bitstream/handle/123456789/16542/the%20projet.pdf?sequence=2&isAllowed=y.
- Australian Government, Department of Health, Therapeutics Goods Administration, Recommended paracetamol doses, 2019. [cited 2021 April 23]. https://www.tga.gov.au/community-qa/recommended-paracetamol-doses.
- Bagel S, Wiedemann B. Extension of in-use stability of preservative-free nasalia. Eur J Pharm Biopharm. 2004;57(2):353–358.
- Linne-Geyer S, Stahl K, Pieper T. In-use stability of aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in a dry powder inhaler. Thorax. 2016;71(Suppl 3):A249–A251.
- DailyMed, Duaklir Pressair - Aclidinium bromide and Formoterol fumarte powder, metered, Circassia Pharmaceuticals Inc. [cited 2021 April 23]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb24d6b0-0d69-4a3c-a7f4-a35ca4804657.
- Yue B, Brendel R, Lukitsch A, et al. Solubility and stability of baclofen 3 mg/ml intrathecal formulation and its compatibility with implantable programmable intrathecal infusion systems. Neuromodulation. 2017;20(4):397–404.
- Electronic Medicines Compendium, Lioresal Intrathecal Infusion 10mg/5ml, SmPC, Novartis Pharmaceuticals UK Ltd, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/7790/smpc.
- Park D, Kim J, Yun J, et al. Evaluation of the physico-chemical and biological stability of SB8 (aybintio), a proposed biosimilar to bevacizumab, under ambient and in-use conditions. Adv Ther. 2020;37(10):4308–4324.
- Electronic Medicines Compendium, Aybintio 25 mg/ml concentrate for solution for infusion, SmPC, Organon Pharma (UK) Limited, 2021. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/11801.
- Bhattacharya S, Parekh S, Dedhiya M. In-use stability of ceftaroline fosamil in elastomeric home infusion systems and MINI-BAG plus containers. Int J Pharm Compd. 2015;19:432–436.
- Electronic Medicines Compendium, Zinforo 600 mg powder for concentrate for solution for infusion, SmPC, Pfizer Limited, 2021. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/4297.
- Sandor K, Terzic S, Andrisic M, et al. In-use stability of enrofloxacin solution for injection in multi-dose containers. Acta Vet (Beogr). 2012;62(2–3):213–225.
- Zoo Farm Agro, Enroxil 10% solution for injection. [cited 2021 April 24]. http://zoofarmagro.md/en/catalog-de-produse/enroxil-10-solutie-injectabila/#:∼:text=Enroxil%C2%AE%2010%25%20solution%20for,other%20diseases%20whose%20pathogens%20are.
- Nalenz H, Köpf E, Dietel E. Prolonged in-use stability of reconstituted herceptin in commercial intravenous bags. Int J Pharm Compd. 2018;22(5):417–423.
- Electronic Medicines Compendium, Herceptin 150mg Powder for concentrate for solution for infusion, SmPC, Roche Products Limited, 2021. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/3856.
- Rivano M, Selmin F, Camuffo L, et al. 3PC-019 In use physicochemical and microbiological stability of diluted solutions of the monoclonal antibody Nivolumab. In: Section 3: Production and Compounding, British Medical Journal Publishing Group; 2020. p. A30.1–A30.
- Electronic Medicines Compendium, OPDIVO 10 mg/mL concentrate for solution for infusion, SmPC, Bristol-Myers Squibb Pharmaceuticals limited, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/6888/smpc.
- Al-Nazawi MH. Comparative pharmacokinetic studies on oxytetracycline in camels, sheep and goats, pak. Vet. J. 2003;23:187–191.
- Lamanna WC, Heller K, Schneider D, et al. The in-use stability of the rituximab biosimilar rixathon®/riximyo® upon preparation for intravenous infusion. J Oncol Pharm Pract. 2019;25(2):269–278.
- Electronic Medicines Compendium, Rixathon 100 mg concentrate for solution for infusion, SmPC, Sandoz Limited, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/2714/smpc.
- Mueller C, Dietel E, Heynen SR, et al. Physico-chemical stability of MabThera drug-product solution for subcutaneous injection under in-use conditions with different administration materials. Int J Pharm Compd. 2015;19:261–267.
- Electronic Medicines Compendium, MabThera 1400 mg Solution for Subcutaneous Injection, SmPC, Roche Products Limited, 2021. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/5333/smpc.
- Kim SJ, Lee JW, Kang HY, et al. In-use physicochemical and biological stability of the trastuzumab biosimilar CT-P6 upon preparation for intravenous infusion. BioDrugs. 2018;32(6):619–625.
- Electronic Medicines Compendium, Herzuma 150 mg powder for concentrate for solution for infusion, SmPC, Napp Pharmaceuticals Limited, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/9101/smpc#gref.
- Medicines Evaluation Board Agency, Public Assessment Report, Brinzolamide Pharmathen 10 mg/ml eye drops suspension, July 16, 2015. [cited 2021 April 24]. https://mri.cts-mrp.eu/Human/Downloads/NL_H_2717_001_PAR.pdf.
- Electronic Medicines Compendium, Brinzolamide Eye Drops 10mg/ml x 5ml, Patient Information Leaflet, Zentiva, 2020. https://www.medicines.org.uk/emc/product/8054/pil#gref.
- Electronic Medicines Compendium, Brinzolamide 10mg ml eye drops suspension, SmPC, Zentiva, 2021. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/9394/smpc.
- Shin S, Won Jang K, Sun S, et al. The in-use stability study of multi-use ophthalmic solutions, focused on olopatadine, fluorometholone, dorzolamide. Timolol. J. Korea Acad. Industr. Coop. Soc. 2019;20:681–693.
- Electronic Medicines Compendium, Dorzolamide 20 mg/ml Eye Drops, Solution, SmPC, FDC International Ltd, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/3320/smpc#gref.
- Electronic Medicines Compendium, FML® Liquifilm® Ophthalmic 1 mg/ml eye drops, suspension, SmPC, Allergan Ltd, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/1383/smpc#gref.
- Electronic Medicines Compendium, Opatanol 1mg/ml eye drops solution, SmPC, Novartis Pharmaceuticals UK Ltd, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/6768/smpc#gref.
- Electronic Medicines Compendium, Timolol Eye Drops 0.25%, SmPC, FDC International Ltd, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/459/smpc#gref.
- AlAani H, AlNukkary Y. Determination of benzalkonium chloride in ophthalmic solutions by stability-indicating HPLC method: Application to a stability study. J App Pharm Sci. 2016;6(5):80–89.
- Electronic Medicines Compendium, Dorzolamide 20 mg/ml and Timolol 5 mg/ml Eye Drops, Solution, SmPC, FDC International Ltd, 2021. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/3319/smpc#gref.
- Electronic Medicines Compendium, Xalacom eye drops, solution, SmPC, Upjohn UK Limited, 2020. [cited 2021 April 24]. https://www.medicines.org.uk/emc/product/1536/smpc#gref.
- Waterman KC, Chen L, Waterman P, et al. Modeling of in-use stability for tablets and powders in bottles. Drug Dev Ind Pharm. 2016;42(10):1571–1578.
- Remmelgas J, Simonutti AL, Ronkvist Å, et al. A mechanistic model for the prediction of in-use moisture uptake by packaged dosage forms. Int J Pharm. 2013;441(1–2):316–322.
- Magari RT, Afonina E. In-use stability modeling. J Pharm Biomed Anal. 2011;56(4):799–803.
- Khan MM, Jiang B, Mazzeo A, et al. Stability challenges not addressed by harmonized guidance – AAPS workshop of the stability focus group, april 3rd- 4th, 2017 in rockville, MD. AAPS Open. 2018;4(1):2.